KOREA PHARMA Co., Ltd. (KOSDAQ:032300)
South Korea · Delayed Price · Currency is KRW 8,670.00
+400.00 (4.84%)
At close: Jun 9, 2026
KOREA PHARMA Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 91,417 | 87,601 | 81,277 | 83,240 | 81,029 | 79,577 |
Other Revenue | -0 | -0 | - | -0 | -0 | - |
| 91,417 | 87,601 | 81,277 | 83,240 | 81,029 | 79,577 | |
Revenue Growth (YoY) | 11.78% | 7.78% | -2.36% | 2.73% | 1.83% | 11.28% |
Cost of Revenue | 59,831 | 56,229 | 46,127 | 46,337 | 45,614 | 43,679 |
Gross Profit | 31,586 | 31,372 | 35,150 | 36,903 | 35,415 | 35,898 |
Selling, General & Admin | 26,868 | 27,188 | 25,031 | 25,938 | 24,983 | 24,502 |
Research & Development | 2,543 | 2,433 | 2,053 | 2,313 | 2,452 | 4,893 |
Amortization of Goodwill & Intangibles | 863.4 | 865.84 | 699.3 | 633.42 | 394.95 | 391.54 |
Other Operating Expenses | 567.61 | 559.77 | 530.99 | 561.44 | 622.52 | 611.61 |
Operating Expenses | 31,998 | 32,260 | 29,064 | 31,063 | 29,228 | 30,883 |
Operating Income | -412.02 | -887.33 | 6,086 | 5,840 | 6,187 | 5,014 |
Interest Expense | -3,777 | -3,566 | -2,880 | -3,738 | -3,867 | -908.17 |
Interest & Investment Income | 777.83 | 731.04 | 1,397 | 510.74 | 211.94 | 57.42 |
Earnings From Equity Investments | -448.79 | -278.05 | 1,644 | -1,724 | - | - |
Currency Exchange Gain (Loss) | 91.67 | -36.97 | 162.72 | -39.62 | 26.82 | 18.41 |
Other Non Operating Income (Expenses) | -982.92 | -1,011 | -2,590 | -139.55 | -4,378 | 1,019 |
EBT Excluding Unusual Items | -4,751 | -5,048 | 3,820 | 710.03 | -1,819 | 5,201 |
Gain (Loss) on Sale of Investments | 706.16 | 748.22 | 364.1 | 1,910 | -42.2 | 1.93 |
Gain (Loss) on Sale of Assets | 1.22 | 1.22 | 1.14 | 0.32 | 81.9 | 5.29 |
Asset Writedown | -222.4 | -222.4 | -279.24 | -606.42 | - | - |
Pretax Income | -4,266 | -4,521 | 3,906 | 2,014 | -1,780 | 5,208 |
Income Tax Expense | -1,794 | -1,881 | 114.21 | 1,931 | -660.63 | -1,160 |
Net Income | -2,473 | -2,640 | 3,792 | 83.76 | -1,119 | 6,368 |
Net Income to Common | -2,473 | -2,640 | 3,792 | 83.76 | -1,119 | 6,368 |
Net Income Growth | - | - | 4426.69% | - | - | 101.59% |
Shares Outstanding (Basic) | 11 | 11 | 11 | 10 | 11 | 11 |
Shares Outstanding (Diluted) | 11 | 12 | 11 | 10 | 11 | 11 |
Shares Change (YoY) | -0.33% | 9.75% | 4.06% | -3.63% | -1.22% | 12.80% |
EPS (Basic) | -227.32 | -242.09 | 348.00 | 8.00 | -103.00 | 584.00 |
EPS (Diluted) | -227.32 | -242.09 | 348.00 | 8.00 | -103.00 | 579.00 |
EPS Growth | - | - | 4250.00% | - | - | 78.70% |
Free Cash Flow | -13,857 | -16,957 | 4,797 | 3,288 | 5,815 | 4,640 |
Free Cash Flow Per Share | -1273.91 | -1417.96 | 440.24 | 314.06 | 535.19 | 421.87 |
Gross Margin | 34.55% | 35.81% | 43.25% | 44.33% | 43.71% | 45.11% |
Operating Margin | -0.45% | -1.01% | 7.49% | 7.02% | 7.64% | 6.30% |
Profit Margin | -2.71% | -3.01% | 4.67% | 0.10% | -1.38% | 8.00% |
Free Cash Flow Margin | -15.16% | -19.36% | 5.90% | 3.95% | 7.18% | 5.83% |
EBITDA | 2,714 | 2,280 | 8,883 | 8,653 | 8,567 | 7,391 |
EBITDA Margin | 2.97% | 2.60% | 10.93% | 10.40% | 10.57% | 9.29% |
D&A For EBITDA | 3,126 | 3,167 | 2,797 | 2,813 | 2,380 | 2,377 |
EBIT | -412.02 | -887.33 | 6,086 | 5,840 | 6,187 | 5,014 |
EBIT Margin | -0.45% | -1.01% | 7.49% | 7.02% | 7.64% | 6.30% |
Effective Tax Rate | - | - | 2.92% | 95.84% | - | - |
Advertising Expenses | - | 1,229 | 1,230 | 1,569 | 1,224 | 858.02 |